Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody

Cancer Res (2018) 78 (13_Supplement): 1729.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets

Tatiana Vilela
Sofia Valente
Jorge Correia
Fernando Ferreira

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) 1879 (5): 189144.

VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy

Najibeh Shekari
Dariush Shanehbandi
Tohid Kazemi
Habib Zarredar
Behzad Baradaran
Seyed Amir Jalali

Cancer Cell International (2023) 23 (1)

Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway

Shuai Zheng
Kuojun Zhang
Xiangyu Zhang
Yibei Xiao
Tianyu Wang
Sheng Jiang

Journal of Medicinal Chemistry (2022) 65 (18): 11900.

VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses

Chenyang Wu
Xin Cao
Xiaojin Zhang

RSC Medicinal Chemistry (2021) 12 (10): 1672.

VISTA: Coming of age as a multi-lineage immune checkpoint

M A ElTanbouly
E Schaafsma
R J Noelle
J L Lines

Clinical and Experimental Immunology (2020) 200 (2): 120.